SKP2 and plasma cell myeloma: Another example, the SCFSkp2 components related to BTZ resistance, and combined use of BTZ and Skp2 inhibitor inhibits BTZ-resistant multiple myeloma growth, rendering targeting SCFSkp2as a strategy to overcome therapeutic resistance in multiple myeloma.